Prophase Labs

Prophase Labs Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Prophase Labs (PRPH) as of Oct 30, 2026 is -1.02. In the previous year, Net Debt to Free Cash Flow Ratio was -1.30 — a change of -21.11% (higher).

Net Debt/FCF

-1.02

YoY

-21.11%

Last updated:

Net Debt to Free Cash Flow Ratio of Prophase Labs is 2025 -1.02 . Net Debt to Free Cash Flow Ratio of Prophase Labs was 2024 -1.30 . It decreases by -21.11% higher compared to the previous year.

The Prophase Labs Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
2.06 USD
Jan 1, 2019
0.41 USD
Jan 1, 2020
-1.46 USD
Jan 1, 2021
0.15 USD
Jan 1, 2022
-0.43 USD
Jan 1, 2023
-0.95 USD
Jan 1, 2024
-1.30 USD
Jan 1, 2025
-1.02 USD
The Prophase Labs Net Debt/FCF history
YEARNet Debt/FCFYoY
-1.02-21.11%
-1.30+36.95%
-0.95+122.41%
-0.43-390.67%
0.15-110.00%
-1.46-460.58%
0.41-80.28%
2.06-71.42%
7.20-871.03%
-0.93-2,088.51%
0.05-94.14%
0.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prophase Labs Stock analysis

What does Prophase Labs do? ProPhase Labs, Inc. generates revenue through the sale of over-the-counter consumer healthcare products and dietary supplements. The company develops and markets TK Supplements, featuring LEGENDZ XL for male sexual enhancement, TRIPLE EDGE XL for daily energy and stamina, and SUPER PROSTAFLOW plus for prostate and urinary health. ORXx Complete, a dietary supplement, and ORXx cough/cold drops are also sold to national wholesalers, distributors, and retail chains including pharmacies and mass merchandise stores. The firm targets health-conscious consumers seeking natural solutions through its OTC drug and supplement lines. Its products are distributed via national wholesalers and retailers such as independent and chain drugstores, food stores, and mass merchandise outlets. ProPhase Labs focuses on direct sales to these established retail segments without third-party branding or partnerships. Revenue streams are derived from the consistent demand for male enhancement, energy, and health supplements within the OTC market. The company's product portfolio caters specifically to customers interested in natural health products, with no additional services or digital platforms beyond physical product sales. Prophase Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prophase Labs stock

Net Debt to Free Cash Flow Ratio of Prophase Labs is -1.02 in 2025.

Net Debt to Free Cash Flow Ratio of Prophase Labs changed from -1.30 to -1.02, representing a -21.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Prophase Labs since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Prophase Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Prophase Labs

All Key Metrics — Prophase Labs